PRINCETON, N.J., Oct. 31, 2013 /PRNewswire/ — Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an unmet medical need, announced today submission of a full contract proposal to the National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases. Successful award of the proposal would support a multi-year, multi-million dollar contract for the advanced development of RiVax™ as a vaccine MCM candidate for biodefense threats to protect the public.
http://www.publicwire.com/2013/10/31/sngx-soligenix-submits-niaid-contract-proposal-for-development-of-a-thermostable-ricin-vaccine/
No comments:
Post a Comment